Skip to main content
OpenTrials
Completed

NCT Number: NCT04877782

Modulating the Locus Coeruleus Function

The purpose of this study is to investigate the impact of transcutaneous vagus nerve stimulation (tVNS) on specific brain regions involved in memory and attention processes.

tVNS is a non-invasive and non-pharmacological technique known for targeting the locus coeruleus, a small subcortical nucleus in the brain thought to be involved in the earliest stages of Alzheimer's disease. This nucleus also plays a role in numerous cognitive functions, comprising memory and attention.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

60 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Maastricht University

Maastricht, 6229 ET, Netherlands

About this study

This study is an observational MRI study with a pseudo-randomized single blind cross-over design. The population consists of 30 healthy human volunteers from 60 to 80 years old. These healthy older individuals will be recruited from the community.

After being informed about the study protocol and the potential risks, subjects will be given 1 week to consider their participation.

All participants giving written informed consent will be included in the study. The first session will consist in neuropsychological assessments and a task practice session in the dummy scanner in order to get familiar with the environment. Participants meeting the eligibility criteria will be included for the next sessions.

The second and third sessions are MRI scanning sessions including transcutaneous vagus nerve stimulation. Both the placebo and experimental stimulation conditions will be randomized in a single-blind manner across scanning sessions.

About 7 to 10 weeks after each scanning session and at least 4 days previous to the next MRI session, participant will be asked to fill in an online memory test for assessing potential outlasting effects of the stimulation technique.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Average neuropsychological test results in accordance with normative data corrected for age, education and sex
  • No substantial memory complaints according to the participant
  • Body mass index < 28
  • Non-smoking
  • Right handedness
  • Average/high level of education (minimum 12 years of education)

Exclusion criteria

  • Psychoactive medication use
  • Abuse of alcohol and drugs
  • Cognitive impairment due to alcohol/drug or other substances abuse
  • Recent trans-meridian travel (<2months)
  • Night shift work (<1year)
  • Diabetes if not stable
  • Hypo-/hyper-tension, hypo-/hyper-thyroid if not stable
  • Hypo-tension due to autonomic dysfunction
  • Recent (<5years) or present psychiatric or neurological disorders (anxiety, major depression, schizophrenia, bipolar disorder, psychotic disorder -or treatment for it-, epilepsy, stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, brain surgery, brain trauma, electroshock therapy, kidney dialysis, Ménière's disease, brain infections)
  • Major vascular disorders (e.g. stroke)
  • History of cardiovascular disorders (e.g., severe heart failure, recurrent vasovagal syncopal episodes)
  • Major valvular disorders (e.g., prosthetic valve or hemodynamically relevant valvular disease, unilateral or bilateral vagotomy)
  • Contraindications for scanning (e.g., brain surgery, cardiac pacemaker, metal implants, claustrophobia, body tattoos, reduced vision even after appropriate optical correction)
  • Contraindications for pupil measurements and light exposure (e.g., Cataracts, Glaucoma, detached retina's, eye surgery involving the muscle, penetrating eye wounds, use of cholinesterase inhibitors, anticholinergic eye drop use, droopy eyelids preventing eye measurement).

Treatment and study plan

Transcutaneous vagus verne stimulation

Device

Non-invasive and short electrical stimulation by placing the stimulating electrode at the cymba conchae of the left ear. The reference electrode is placed near the left cymba conchae. It provides a light tingling, massaging feeling in the ear.

Primary outcomes

  1. Pupillometry - Scan session 1

    Time frame: During the first MRI scanning session (55 minutes)

    Measure of pupil size variations during functional tasks. It can be used as a proxy for measuring arousal-related state transitions in brain activity and it allows for a reliable detection of the locus coeruleus activity.

  2. Pupillometry - Scan session 2

    Time frame: During the second MRI scanning session (55 minutes)

    Measure of pupil size variations during functional tasks. It can be used as a proxy for measuring arousal-related state transitions in brain activity and it allows for a reliable detection of the locus coeruleus activity.

  3. Blood oxygen level dependent (BOLD) response - Scan session 1

    Time frame: During the first MRI scanning session (55 minutes)

    This BOLD signal reflects brain activity during the functional tasks. The study focuses on the BOLD-signal in the locus coeruleus and task-relevant networks during the memory and the vigilance tasks.

  4. Blood oxygen level dependent (BOLD) response - Scan session 2

    Time frame: During the second MRI scanning session (55 minutes)

    This BOLD signal reflects brain activity during the functional tasks. The study focuses on the BOLD-signal in the locus coeruleus and task-relevant networks during the memory and the vigilance tasks.

Secondary outcomes

  1. Performance on the online memory task - Post-session 1

    Time frame: Performed from home, 7 to 10 days after the first MRI session and at least 4 days prior to the second session.

    Total accuracy on the face-name association task (from 0 to 100%); Mean reaction time on the face-name association task (from 0 to 4 seconds).

    The higher the total accuracy and the lower the mean reaction time, the better the outcome measure.

  2. Performance on the online memory task - Post-session 2

    Time frame: Performed from home, 7 to 10 days after the second MRI session.

    Total accuracy on the face-name association task (from 0 to 100%); Mean reaction time on the face-name association task (from 0 to 4 seconds).

    The higher the total accuracy and the lower the mean reaction time, the better the outcome measure.

Sponsors and collaborators

Lead sponsor

Maastricht University Medical Center

Other

Collaborators

  • University of Liege

Registry information

Official study title

Boosting a Neuromodulatory System Relevant to Alzheimer's Disease to Enhance Memory

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
May 7, 2021
Registry last updated
Oct 23, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.